Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

Drugs & Targets

NeoGenomics launches NGS assay for AML

AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.

October 11, 2024

Vol.50 No.38

Drugs & Targets

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Labcorp announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing clinical applications, including molecular residual disease in patients with early-stage solid tumor cancers.

August 02, 2024

Vol.50 No.31

Clinical Trials & Tribulations

Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot

The initial foray into genomic sequencing two decades ago has led to the discovery of key driver mutations and spurred drug development, thereby transforming the management of imminently lethal diseases.

Strata Oncology, Carbone Cancer Center integrate StrataNGS test results with Epic Genomics Module

Strata Oncology Inc announced the integration of discrete genomic data from its StrataNGS NGS-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.

September 16, 2022

Vol.48 No.33

Fate of Illumina-GRAIL $7.1B merger uncertain as (1) EU blocks it, (2) FTC administrative law judge jettisons agency’s opposition

European regulators have prohibited the already-implemented $7.1 billion merger of Illumina and GRAIL, stating that the deal “would have stifled innovation, and reduced choice in the emerging market for blood-based early cancer detection tests.”

September 09, 2022

Vol.48 No.32

By Paul Goldberg

Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

YOU MAY BE INTERESTED IN

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

NeoGenomics launches NGS assay for AML

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot

Strata Oncology, Carbone Cancer Center integrate StrataNGS test results with Epic Genomics Module

Fate of Illumina-GRAIL $7.1B merger uncertain as (1) EU blocks it, (2) FTC administrative law judge jettisons agency’s opposition

Renew today!

Subscriber content

Never miss an issue!

Login